ABOUT US

Luke Beshar

Luke Beshar

Chairman

Luke Beshar has served on Protara’s board of directors since October 2018 and as its Chairman since October 2019. Luke previously served as the Executive Vice President and Chief Financial Officer of NPS Pharmaceuticals, Inc…

LUKE BESHAR

Chairman

Luke Beshar has served on Protara’s board of directors since October 2018 and as its Chairman since October 2019. Luke previously served as the Executive Vice President and Chief Financial Officer of NPS Pharmaceuticals, Inc., a global biopharmaceutical Company, from 2007 to 2015. He is the former Chief Financial Officer of various public and private companies and has more than 35 years of general and financial management experience. Luke served as Executive Vice President, Strategy and Corporate Development, Executive Vice President and Chief Financial Officer of Cambrex Corp. from 2002 to 2007 and previously as Chief Financial Officer at Dendrite Int’l., a provider of services to the life sciences industry. Luke began his career with Arthur Andersen & Co. in 1980 and is a CPA. He holds a BA degree in Accounting and Financial Management from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia. He currently serves on the boards of directors of REGENXBIO, Inc. and Trillium Therapeutics Inc.

read more

MICHAEL SOLOMON, PhD

Director

Dr. Michael Solomon has served on Protara’s board of directors since May 2018. He serves as Chief Executive Officer of Ribometrix, Inc., a company focused on targeting RNA with small molecules…

MICHAEL SOLOMON, PhD

Director

Dr. Michael Solomon has served on Protara’s board of directors since May 2018. He serves as Chief Executive Officer of Ribometrix, Inc., a company focused on targeting RNA with small molecules, and has over 20 years of experience in the biotech industry, with the last 14 years focused on creating and operating early stage companies. Most recently, Dr. Solomon served as a Venture Partner at SV Health Investors from December 2016 until December 2018 and as Chief Operating Officer at Decibel Therapeutics, Inc., a biotech company focused on hearing disorders, from 2015 until 2016, where he led the creation of Decibel’s business plan and its capital raise of $52 million. Previously, he was Chief Operating Officer at Ember Therapeutics, Inc. and Chief Business Officer at Link Medicine Corporation, a CNS company that was sold to Astra Zeneca. Dr. Solomon was a Founder and Vice President of Discovery at Epizyme Therapeutics, Inc. and Vice President of Discovery at Hypnion, Inc., a sleep disorder company that was sold to Lilly in 2007. He began his career at Millennium Pharmaceuticals, where he was a project leader for multiple programs. Dr. Solomon holds a BS in Chemistry from the University of Massachusetts, Amherst; a PhD in Organic Chemistry from the University of Wisconsin; and completed postdoctoral work in synthetic organic chemistry at Scripps.

read more
Michael Solomon, PhD
Scott Braunstein, MD

Scott Braunstein, MD

Director

Dr. Scott Braunstein has served on Protara’s board of directors since June 2018. In August 2019, Dr. Braunstein began serving as President and Chief Executive Officer of Marinus Pharmaceuticals, Inc…

SCOTT BRAUNSTEIN, MD

Director

Dr. Scott Braunstein has served on Protara’s board of directors since June 2018. In August 2019, Dr. Braunstein began serving as President and Chief Executive Officer of Marinus Pharmaceuticals, Inc. and has served as an Operating Partner at Aisling Capital, a leading life sciences investment firm, since September 2015. He previously served as Chief Operating Officer, Chief Strategy Officer, and Senior Vice President of Strategy and Corporate Development at Pacira Pharmaceuticals, Inc. from 2015 to 2018. Prior to Pacira, Dr. Braunstein spent 12 years in various positions at J.P. Morgan Asset Management, most recently as a Managing Director, Senior Portfolio Manager, where he invested in and conducted diligence on a wide variety of pharmaceutical products and product candidates. He currently serves as a member of the boards of directors of Constellation Pharmaceuticals, Inc., Esperion Therapeutics, Inc., STAT Medical, Trevena, Inc., Marinus Pharmaceuticals, Inc., Ziopharm Oncology, Inc. and SiteOne Therapeutics, Inc. Dr. Braunstein holds a BA from Cornell University, an MD from the Albert Einstein College of Medicine and completed his residency in internal medicine at Cornell University-New York Hospital.

read more

Roger Garceau, MD

Director

Dr. Roger Garceau has served on Protara’s board of directors since January 2019 and has more than 30 years of broad pharmaceutical industry experience in drugs, biologics and combination drug/device products for…

ROGER GARCEAU, MD

Director

Dr. Roger Garceau has served on Protara’s board of directors since January 2019 and has more than 30 years of broad pharmaceutical industry experience in drugs, biologics and combination drug/device products for orphan and non-orphan indications, both in the U.S. and Internationally. He previously served as Chief Medical Officer and Executive Vice President of NPS Pharmaceuticals, Inc. since December 2008 and January 2013 respectively, until February 2015, when NPS Pharmaceuticals was acquired by Shire plc. At NPS Dr. Garceau led two successful orphan products through filing, Advisory Committees and registrations. Previously, he served in several managerial positions with NPS Pharmaceuticals, Inc., Sanofi-Aventis and Pharmacia Corporation. He has been a non-executive director of Enterome SA since December 2016 and Entera Bio since March 2016. Dr. Garceau is a board-certified pediatrician and is a Fellow of the American Academy of Pediatrics. He holds a BS in Biology from Fairfield University in Fairfield, Connecticut and an MD from the University of Massachusetts Medical School.

read more
Roger Garceau, MD
Greg Sargen

Greg Sargen

Director

Greg Sargen has served on Protara’s board of directors since November 2019 and is a licensed CPA (inactive) with extensive experience working within the healthcare industry. Greg currently serves as Chief Financial Officer…

GREG SARGEN

Director

Greg Sargen has served on Protara’s board of directors since November 2019 and is a licensed CPA (inactive) with extensive experience working within the healthcare industry. Greg currently serves as Chief Financial Officer and Executive Vice President of Corporate Development and Strategy at Cambrex Corporation. Previously, he served as Executive Vice President and Chief Financial Officer at Expanets, Inc., and Vice President of Finance – Chemicals Manufacturing Division at Fisher Scientific International Inc. Prior to that, Greg held senior positions with Merck & Co., Inc., Heat and Control, Inc. and Deloitte & Touche LLP. His board experience includes his current role as a director of Avid Bioservices. Greg holds a BA in Accounting from Pennsylvania State University and an MBA in Finance from The Wharton School of the University of Pennsylvania.

read more

Richard Levy, MD

Director

Dr. Richard Levy has served on Protara’s board of directors since December 2019 and has more than 25 years of experience in the pharmaceutical and biotechnology industries…

RICHARD LEVY, MD

Director

Dr. Richard Levy has served on Protara’s board of directors since December 2019 and has more than 25 years of experience in the pharmaceutical and biotechnology industries. He is board certified in internal medicine and gastroenterology. Dr. Levy currently serves on the boards of directors of various biopharmaceutical companies, including Madrigal Pharmaceuticals, Inc., Kodiak Sciences, Inc. and Kiniksa Pharmaceuticals, Ltd. Additionally, Dr. Levy recently served as a part-time Senior Advisor for Baker Bros. Advisors, L.P. Prior to Dr. Levy’s board experience, he held an array of executive positions in the pharmaceutical industry, including in drug development, regulatory affairs and pharmacovigilance, clinical research, as well as medical and commercial strategy. Most recently, he served as Executive Vice President and Chief Drug Development Officer at Incyte from January 2009 until he retired in April 2016. His extensive industry experience includes positions at Celgene Corporation, DuPont Pharmaceuticals Company, Sandoz and Novartis. Dr. Levy holds a BA in Biology from Brown University and an MD from the University of Pennsylvania School of Medicine. He completed his training in internal medicine at the Hospital of the University of Pennsylvania and a fellowship in gastroenterology and hepatology at the University of California, Los Angeles.

read more
Richard Levy, MD
Scroll to Top